WO2012033070A1 - 疼痛治療剤 - Google Patents
疼痛治療剤 Download PDFInfo
- Publication number
- WO2012033070A1 WO2012033070A1 PCT/JP2011/070205 JP2011070205W WO2012033070A1 WO 2012033070 A1 WO2012033070 A1 WO 2012033070A1 JP 2011070205 W JP2011070205 W JP 2011070205W WO 2012033070 A1 WO2012033070 A1 WO 2012033070A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pain
- methyl
- formula
- lower alkyl
- compound
- Prior art date
Links
- 0 C1C2C1CC**2 Chemical compound C1C2C1CC**2 0.000 description 5
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to a pharmaceutical composition useful as a therapeutic agent for pain, particularly neuropathic pain and fibromyalgia.
- Pain There are various classifications of pain, but depending on the period and nature, acute pain that acts as a biological warning system and chronic that can continue to be complained even though the disease has exceeded the period necessary for normal healing It is divided into pain. Depending on the cause, there are three main categories: nociceptive pain, neuropathic pain, and psychogenic pain. Neuropathic pain is refractory chronic pain that results from abnormal functioning of the peripheral or central nervous system.
- Typical neuropathic pain includes pain associated with diabetic neuropathy, postherpetic neuralgia, lower back pain, trigeminal neuralgia, cancer pain, postoperative or posttraumatic prolonged pain, pain due to spinal cord injury, Thalamic pain, pain due to multiple sclerosis, complex regional pain syndrome (CRPS), phantom limb pain, HIV-related neuropathic pain and the like.
- the onset mechanism has many unclear points, but it is thought to be caused by abnormal continuous firing of sensory nerves.
- Representative symptoms of neuropathic pain include allodynia, hyperalgesia or hypersensitivity. These symptoms present characteristic pains such as “burning”, “sticking with a needle” or “like electric shock”.
- Non-patent Document 1 Neurosurgical treatments such as nerve block and spinal epidural electrical stimulation, antidepressants (Non-patent document 2), anti-epileptic drugs (Non-patent document 3) and the like have been used as treatment methods for neuropathic pain. However, no safe and effective treatment has been established.
- pregabalin which is a ligand of the ⁇ 2 ⁇ subunit of the voltage-gated calcium channel
- the effectiveness rate is not so high, and there are problems in side effects such as sleepiness and wandering.
- a safe and effective treatment for neuropathic pain has not been established yet, and there is a strong demand for the development of a superior therapeutic agent that has sufficient effects and few side effects.
- Fibromyalgia is a chronic pain disorder with various accompanying symptoms such as insomnia, general fatigue and depressive symptoms, with chronic pain that cannot be tolerated as a core symptom.
- the symptoms of fibromyalgia are extremely diverse.
- As a pain symptom of fibromyalgia it is characterized by chronic pain in deep tissues such as muscle tissue and pain during acupressure.
- allodynia such as tactile allodynia and cold allodynia, and thermal hyperalgesia are often accompanied.
- Fibromyalgia patients also have emotional disorders such as depression and anxiety, fatigue, and other pain disorders (such as neuropathic pain, rheumatism, osteoarthritis of the knee, postoperative acute pain) High rate of accompanying symptoms such as sleep disorders and irritable bowel syndrome.
- emotional disorders such as depression and anxiety, fatigue, and other pain disorders (such as neuropathic pain, rheumatism, osteoarthritis of the knee, postoperative acute pain)
- High rate of accompanying symptoms such as sleep disorders and irritable bowel syndrome.
- the organic disorder or functional disorder causing the pain is somewhat clear, whereas in fibromyalgia patients, the cause of the pain is not clear.
- Diagnosis criteria for fibromyalgia is the American College of Rheumatology (the American American College of Rheumatology), where extensive pain in the body has continued for more than 3 months, and is in the whole body (ligaments, tendons, muscles that touch the bone, etc.) ) It is determined that tenderness is observed in 11 or more of 18 tender points (Non-Patent Document 4). This diagnostic criterion is clearly different from diagnostic criteria for other pain disorders. That is, fibromyalgia is an independent chronic disease that is clearly different from other pain diseases in terms of symptoms, causes of pain, diagnostic criteria, and the like.
- Non-patent document 5 drugs such as pregabalin (Non-patent document 5), SNRI (serotonin / noradrenaline reuptake inhibitor) duloxetine (Non-patent document 6), and dopamine agonist pramipexole (Non-patent document 7) have been used as fibromyalgia. Although it has been reported that the pain symptom scores of patients with symptomatology are statistically significantly reduced compared with the placebo group, the effects of these agents are limited. There has not yet been established a safe and effective treatment for fibromyalgia, and there is a strong demand for the development of a superior therapeutic agent that has sufficient effects and few side effects.
- Glucocorticoids are hormones that cause metabolic abnormalities such as hyperglycemia, insulin resistance, obesity, hyperlipidemia, and hypertension, and are not only produced from the adrenal glands but also converted from inactive to active forms at the tissue level, Acts through its receptor.
- 11 ⁇ -hydroxysteroid dehydrogenase (11 ⁇ -HSD) is an enzyme that catalyzes this conversion, and it is known that there are two subtypes.
- 11 ⁇ -Hydroxysteroid dehydrogenase type 1 (11 ⁇ -HSD1) is an enzyme that converts an inactive form into an active form and is highly expressed in the liver
- 11 ⁇ -hydroxysteroid dehydrogenase type 2 (11 ⁇ -HSD2) is an inactive form. It is an enzyme that converts and is highly expressed in the kidney.
- 11 ⁇ -HSD1 has a wide range of substrate specificities (Non-patent Document 8), but its relationship with glucocorticoid is best known.
- 11 ⁇ -HSD1 knockout mice exhibit improved glucose tolerance, decreased blood triglycerides, increased HDL-cholesterol (Non-patent Document 9), non-selective 11 ⁇ -HSD inhibitor carbenoxolone is inactive in mouse pancreatic ⁇ -cells 11 ⁇ -HSD1 selective inhibitor inhibits conversion to active glucocorticoid by inhibiting the conversion to active glucocorticoid, since there is a report such as improvement of insulin secretion decrease by addition of type glucocorticoid (Non-patent Document 10). It is expected to suppress the action and to correct metabolic abnormalities such as hyperglycemia, insulin resistance, obesity, hyperlipidemia, and hypertension caused by glucocorticoids as a result (Patent Document 1).
- 11 ⁇ -HSD1 is also expressed in the central nervous system such as the brain and spinal cord (Non-patent Documents 11 and 12).
- Examples of 11 ⁇ -HSD1 inhibitors include reports in Patent Documents 1 to 11.
- a triazole compound represented by the following general formula (A) has an 11 ⁇ -HSD1 inhibitory action, and is diabetes, hyperglycemia, insulin resistance, obesity, hyperlipidemia, hypertension, osteoporosis, glaucoma, cognition It is described that it is useful for the treatment of diseases such as symptom, schizophrenia and depression. However, there is no description about the usefulness for the treatment of pain. (See the official gazette for symbols in the formula.)
- a triazole compound represented by the following general formula (B) has an inhibitory action on 11 ⁇ -HSD1, and diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension It is described that it is useful for treatment of metabolic syndrome and the like. However, there is no description about the usefulness for the treatment of pain. (See the official gazette for symbols in the formula)
- the triazole compound represented by the following general formula (C) has an 11 ⁇ -HSD1 inhibitory action, and is diabetic, hyperglycemia, hypertension, obesity, insulin resistance, dyslipidemia, high It is described that it is useful for the treatment of lipemia, hypertension, X syndrome and the like. However, there is no description about the usefulness for the treatment of pain. (See the official gazette for symbols in the formula.)
- Patent Document 5 describes that a triazole compound represented by the following general formula (D) has an 11 ⁇ -HSD1 inhibitory action and is useful for the treatment of diabetes, obesity, and metabolic syndrome. However, there is no description about the usefulness for the treatment of pain. (Z in the formula is-(CH (R 14 )) p-,-(CH (R 14 )) pN (R 16 )-(CH (R 15 )) q- or Indicates. For other symbols, see the publication. )
- a triazole compound represented by the following general formula (E) has 11 ⁇ -HSD1 inhibitory action, and is diabetic, hyperglycemia, insulin resistance, obesity, hyperlipidemia, hypertension, osteoporosis, glaucoma, cognition. It is described that it is useful for the treatment of diseases such as reduced function. However, there is no description about the usefulness for the treatment of pain. (See the official gazette for symbols in the formula.)
- a triazole compound represented by the following general formula (F) has an 11 ⁇ -HSD1 inhibitory action, and is diabetes, hyperglycemia, insulin resistance, obesity, hyperlipidemia, hypertension, osteoporosis, glaucoma, cognition It is described that it is useful for the treatment of diseases such as reduced function. However, there is no description about the usefulness for the treatment of pain.
- R 1 represents a heterocyclic group or —N (R 0 ) —R 4
- a and B represent lower alkyl, or a cycloalkyl ring together with the carbon atom to which they are bonded.
- a compound represented by the following general formula (G) has an 11 ⁇ -HSD1 inhibitory action, and is diabetic, metabolic syndrome, insulin resistance, obesity, glaucoma, hyperglycemia, hyperinsulinemia, osteoporosis, tuberculosis.
- Atherosclerosis, Dementia, Depression, Viral diseases, Inflammatory diseases, Liver is described as being useful for the treatment of targeted diseases.
- pain among diseases exemplified as inflammatory diseases but there is no description of neuropathic pain and fibromyalgia. (See the official gazette for symbols in the formula.)
- a compound represented by the following general formula (H) has an 11 ⁇ -HSD1 inhibitory action, and is diabetic, metabolic syndrome, insulin resistance, obesity, glaucoma, hyperglycemia, hyperinsulinemia, osteoporosis, atheroma Atherosclerosis, dementia, depression, viral diseases, inflammatory diseases, liver are described as useful for the treatment of target diseases.
- a compound represented by the following general formula (J) has an 11 ⁇ -HSD1 inhibitory action, and is diabetic, metabolic syndrome, insulin resistance, obesity, glaucoma, hyperglycemia, hyperinsulinemia, osteoporosis, atheroma Atherosclerosis, dementia, depression, viral diseases, inflammatory diseases, liver are described as being useful for the treatment of target diseases.
- an 11 ⁇ -HSD1 inhibitor such as a compound represented by the following formula (K) is used for inflammation, chronic inflammation, pain, rheumatoid arthritis (RA), osteoarthritis (OA). It is described that it is useful for the treatment of), and as a specific example of pain, pain associated with neuropathic pain and fibromyalgia is described.
- K a compound represented by the following formula
- RA rheumatoid arthritis
- OA osteoarthritis
- the subject of the present invention is to provide a medicament useful for the treatment of pain (particularly neuropathic pain, fibromyalgia).
- the present inventors conducted extensive studies using pain model animals for the purpose of providing a therapeutic agent for pain. As a result, it has been found that a compound having 11 ⁇ -HSD1 inhibitory activity, in particular, a triazole compound characterized by having a ring group at the 3-position (or 5-position) of the triazole ring exhibits a good chronic pain-improving effect,
- the present invention has been completed. That is, the present invention (1) An agent for treating pain comprising a compound represented by the formula (Ia) or a pharmaceutically acceptable salt thereof as an active ingredient [The symbols in the formula have the following meanings. Ring A: aryl, heterocyclic group, or cycloalkyl, each optionally substituted.
- R 1a aryl or heterocyclic group each optionally substituted, or lower alkylene-cycloalkyl.
- R 2a lower alkyl.
- R 3a —H or lower alkyl. Alternatively, R 2a and R 3a are combined to form C 2-6 alkylene.
- R 4 lower alkyl, halogeno lower alkyl, lower alkylene-O-lower alkyl, cycloalkyl, lower alkylene-S-lower alkyl, lower alkylene-S (O) -lower alkyl, lower alkylene-S (O) 2 -lower Alkyl or lower alkylene-cycloalkyl. (The same applies hereinafter.)] (2) The pain therapeutic agent according to (1), wherein the pain is neuropathic pain. (3) The pain therapeutic agent according to (1), wherein the pain is fibromyalgia. About.
- the present invention also relates to a compound of formula (Ia) or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical composition for the prevention or treatment of pain (particularly neuropathic pain, fibromyalgia).
- a pharmaceutical composition for the prevention or treatment of pain (particularly neuropathic pain, fibromyalgia).
- Use of salts, compounds of formula (Ia) or salts thereof for use in the treatment of pain (especially neuropathic pain, fibromyalgia), and compounds of formula (Ia) or salts thereof It also relates to a method for treating pain comprising administering an effective amount to a subject. That is, the present invention (4) Use of a compound represented by the formula (Ia) or a pharmaceutically acceptable salt thereof for the manufacture of a therapeutic agent for pain.
- a compound represented by formula (Ia) or a pharmaceutically acceptable salt thereof for the treatment of pain (6)
- a compound represented by formula (Ia) or a pharmaceutically acceptable salt thereof for the treatment of pain (7)
- a method for treating pain comprising administering to a patient a therapeutically effective amount of a compound represented by the formula (Ia) or a pharmaceutically acceptable salt thereof. Also related.
- the present invention provides (8) It also relates to a therapeutic agent for fibromyalgia containing an 11 ⁇ -HSD1 inhibitor as an active ingredient.
- “Lower alkyl” is preferably linear or branched alkyl having 1 to 6 carbon atoms (hereinafter abbreviated as C 1-6 ), specifically, methyl, ethyl, n-propyl, isopropyl, n -Butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl group and the like. More preferred is C 1-4 alkyl, and particularly preferred are methyl, ethyl, n-propyl and isopropyl.
- C 1-6 alkylene preferably linear or branched, as “lower alkylene”, specifically methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, propylene, methylmethylene, ethylethylene, 1 1,2-dimethylethylene, 1,1,2,2-tetramethylethylene group and the like. More preferred is C 1-4 alkylene, and particularly preferred are methylene, ethylene and trimethylene.
- Halogen means F, Cl, Br, I.
- a “halogeno lower alkyl” is a lower alkyl substituted with one or more halogens. Preferred is lower alkyl substituted with 1 to 7 halogens, more preferred is lower alkyl substituted with 1 to 5 halogens, and even more preferred is fluoromethyl, difluoromethyl, trifluoromethyl. It is.
- a “halogeno lower alkylene” is a lower alkylene substituted with one or more halogens. Preferred is lower alkylene substituted with 1 to 7 halogens, and more preferred are fluoromethylene, difluoromethylene, trifluoromethylmethylene and bistrifluoromethylmethylene.
- Cycloalkyl is a C 3-10 saturated hydrocarbon ring group, which may have a bridge. Specific examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl groups, and the like. C 3-8 cycloalkyl is preferable, and cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl are more preferable.
- Cycloalkenyl is C 3-15 cycloalkenyl, which may have a bridge, and includes a cyclic group condensed with a benzene ring at a double bond site. Specific examples include cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, 1-tetrahydronaphthyl, 1-indenyl, and 9-fluorenyl groups. More preferred is C 5-10 cycloalkenyl, and particularly preferred are cyclopentenyl and cyclohexenyl.
- Aryl is a C 6-14 monocyclic to tricyclic aromatic hydrocarbon ring group, preferably phenyl or naphthyl, and more preferably phenyl.
- Heterocycle group means i) a monocyclic 3 to 8 membered (preferably 5 to 7 membered) heterocyclic ring containing 1 to 4 heteroatoms selected from O, S and N, ii) the monocyclic ring A heterocyclic ring and one or two rings selected from the group consisting of a monocyclic hetero ring, a benzene ring, a C 5-8 cycloalkane and a C 5-8 cycloalkene are condensed to form O, Bicyclic 8-14 membered (preferably 9-11 membered) heterocyclic and tricyclic 11-20 membered (preferably 12-15 membered) heterocyclic containing 1-5 heteroatoms selected from S and N
- the ring group which consists of a ring is meant.
- the ring atom S or N may be oxidized to form an oxide or a dioxide.
- Preferred as ⁇ heterocyclic '' groups are aziridinyl, azetidyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, homomorpholinyl, tetrahydrothiopyranyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, , Pyridyl, pyrimidinyl, pyrazinyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, indolyl, isoindolinyl,
- Heteroaryl means an aromatic group among the above-mentioned “heterocycle” groups. Specifically, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, indolyl, indazolyl, benzimidazolyl, imidazo [1,2-a ] Pyridinyl, quinoxalinyl, quinolyl, isoquinolyl, quinazolyl, cinnonyl, phthalazyl, benzofuranyl, benzothienyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, carbazolyl.
- Monocyclic heteroaryl is preferable, and pyridyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, and thiadiazolyl are more preferable.
- R 0 means —H or lower alkyl
- R 0 means —H or lower alkyl
- R 0 means —H or lower alkyl
- G 1 group halogen, cyano, lower alkyl, halogeno lower alkyl, lower alkylene-OR 0 , lower alkylene-N (R 0 ) 2 , lower alkylene-N (R 0 ) C (O) R 0 , lower alkylene-N (R 0 ) S (O) 2 -lower alkyl, -OR 0 , -O-halogeno lower alkyl, -O-cycloalkyl, -O-aryl, -O-heterocyclic group, -C (O) R 0 , -CO 2 R 0, -C ( O) NH 2, -C (O) N (R 0) - (- oR 0 or -CO 2 R 0 lower alkyl which may be substituted with), - C ( O) N (R 0 ) -lower alkylene-OR 0 , -C (O) N (R 0 ) -lower alky
- G 2 group halogen, cyano, lower alkyl, halogeno lower alkyl, —OR 0 , —O-halogeno lower alkyl, —CO 2 R 0 , —C (O) N (R 0 ) 2 , —C (O) N (R 0 ) S (O) 2 -lower alkyl, —C (O) N (R 0 ) S (O) 2 N (R 0 ) 2 , cycloalkyl, and a heterocyclic group.
- the substituent in the “aryl”, “heterocyclic group” and “cycloalkyl” which may each be substituted in the A ring is preferably a group selected from the following G 3 group, more preferably halogen, lower Alkyl, halogeno lower alkyl, —O-lower alkyl, —O-halogeno lower alkyl and —C (O) NH 2 are preferred, and halogen, halogeno lower alkyl or —C (O) NH 2 is more preferred.
- Group G 3 halogen, cyano, lower alkyl, halogeno-lower alkyl, lower alkylene -OR 0, halogeno-lower alkylene -OR 0, lower alkylene -N (R 0) 2, lower alkylene - aryl, -OR 0, -O- Halogeno lower alkyl, -O-lower alkylene-OR 0 , -O-lower alkylene-N (R 0 ) 2 , -O-lower alkylene-CO 2 R 0 , -O-lower alkylene-C (O) N (R 0) 2, -O- lower alkylene - aryl, -O- aryl, -C (O) R 0, -CO 2 R 0, -CON (R 0) 2, -CON (R 0) - lower alkylene -OR 0 , -N (R 0 ) 2 , -N (R 0 ) C (O) R
- the aryl and heterocyclic groups in the G 3 group are substituted with halogen, lower alkyl, halogeno lower alkyl, —OR 0 , —O-halogeno lower alkyl, —CO 2 R 0 or —CON (R 0 ) 2 May be.
- the substituent in the optionally substituted “aryl” in R 1b is preferably halogen, lower alkyl, halogeno lower alkyl, —O-lower alkyl, —O-halogeno lower alkyl, more preferably halogen. is there.
- halogen, lower alkyl, halogeno lower alkyl, —O-lower alkyl, —O-halogeno lower alkyl or -C (O) are NH 2, more preferably halogen, halogeno-lower alkyl or -C (O) NH 2.
- the “11 ⁇ -HSD1 inhibitor” is a compound that inhibits the enzyme activity of 11 ⁇ -HSD1, and is not particularly limited as long as it is effective for pain.
- the compound has an IC 50 value of 10 ⁇ M or less, more preferably 3 ⁇ M or less, and still more preferably.
- the compound is 1 ⁇ M or less.
- the “pain” is preferably neuropathic pain. In another embodiment, fibromyalgia is preferable.
- a compound represented by formula (Ib) which is an active ingredient of the medicament of the present invention.
- a compound represented by formula (Ib) [The symbols in the formula have the following meanings.
- R 1b aryl which may be substituted.
- R 2b lower alkyl.
- R 3b lower alkyl.
- R 4b lower alkyl or cycloalkyl.
- a ring b aryl or heteroaryl each optionally substituted.
- a compound represented by formula (Ic) [The symbols in the formula have the following meanings.
- R 1c Phenyl substituted with halogen.
- R 4c methyl, ethyl, isopropyl or cyclopropyl.
- Ring A c phenyl substituted with halogen or —C (O) NH 2 .
- R 1a is preferably an optionally substituted aryl, more preferably an optionally substituted phenyl, still more preferably a phenyl substituted with a halogen, and even more Preferred is phenyl substituted at the 2-position and 4-position with halogen, or phenyl substituted at the 2-position, 4-position and 6-position with halogen.
- R 2a is preferably lower alkyl, and more preferably methyl.
- R 3a is preferably lower alkyl, and more preferably methyl.
- R 4 is preferably lower alkyl or cycloalkyl, and more preferably methyl, ethyl, isopropyl, or cyclopropyl.
- a ring is preferably an aryl or heteroaryl, each of which may be substituted, more preferably an aryl which may be substituted, and still more preferably an optionally substituted phenyl. And even more preferably phenyl substituted with halogen or —C (O) NH 2 , even more preferably phenyl substituted with halogen, particularly preferably phenyl substituted with halogen at the 2-position Or phenyl substituted at the 2-position and 4-position with halogen.
- Another embodiment is preferably phenyl substituted with —C (O) NH 2 and further optionally substituted with halogen, more preferably 4-position is substituted with —C (O) NH 2 , and Phenyl optionally substituted with halogen.
- phenyl or pyrrole each substituted with a group selected from halogen, halogeno lower alkyl and —C (O) NH 2 is preferred.
- F A compound which is a combination of two or more of the groups described in (a) to (e) above.
- the compound of formula (Ia), which is an active ingredient of the medicament of the present invention may have tautomers and geometric isomers depending on the type of substituent.
- the compound of the formula (Ia) may be described in only one form of an isomer, but the active ingredient of the medicament of the present invention includes other isomers, Also included are those separated, or mixtures thereof.
- the compound of formula (Ia) which is an active ingredient of the medicament of the present invention may have an asymmetric carbon atom or axial asymmetry, and optical isomers based on this may exist.
- the active ingredients of the medicament of the present invention include those in which optical isomers are separated or a mixture thereof.
- the compound of formula (Ia), which is an active ingredient of the medicament of the present invention includes pharmaceutically acceptable prodrugs.
- a pharmaceutically acceptable prodrug is a compound having a group that can be converted to an amino group, a hydroxyl group, a carboxyl group, or the like by solvolysis or under physiological conditions. Examples of groups that form prodrugs include those described in Prog. Med., 5, 2157-2161 (1985) and “Development of pharmaceuticals” (Yodogawa Shoten, 1990), Volume 7, Molecular Design 163-198. Is mentioned.
- the compound of the formula (Ia) which is an active ingredient of the medicament of the present invention may form an acid addition salt or a salt with a base depending on the kind of the substituent.
- inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid Acid addition with organic acids such as lactic acid, malic acid, mandelic acid, tartaric acid, dibenzoyl tartaric acid, ditoluoyl tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, aspartic acid, glutamic acid Salts, salts with inorganic bases such as sodium, potassium, magnesium, calcium and aluminum, salts with organic acids with organic
- the compound of formula (Ia), which is an active ingredient of the medicament of the present invention includes various hydrates, solvates, and crystalline polymorphic substances.
- the compound of the formula (Ia) which is an active ingredient of the medicament of the present invention includes compounds labeled with various radioactive or non-radioactive isotopes.
- the compound of formula (Ia) and the salt thereof, which are the active ingredients of the medicament of the present invention can be produced by applying various known synthetic methods utilizing the characteristics based on the basic structure or the type of substituent. it can. At that time, depending on the type of functional group, it is effective in terms of production technology to replace the functional group with an appropriate protective group (a group that can be easily converted into the functional group) at the stage from the raw material to the intermediate. There is a case.
- protecting groups include protecting groups described in “Greene's Protective Groups in Organic Synthesis (4th edition, 2006)” by PGM Wuts and TW Greene. These may be appropriately selected according to the reaction conditions.
- the desired compound after carrying out the reaction by introducing the protective group, the desired compound can be obtained by removing the protective group as necessary.
- the prodrug of the compound of the formula (Ia) introduces a specific group at the stage from the raw material to the intermediate, or uses the obtained compound of the formula (Ia), like the above protecting group.
- it can manufacture by performing reaction.
- the reaction can be carried out by applying a method known to those skilled in the art, such as ordinary esterification, amidation, dehydration and the like.
- typical production methods of the compound of the formula (Ia) will be described. Each manufacturing method can also be performed with reference to the reference attached to the said description.
- the manufacturing method of this invention is not limited to the example shown below.
- L 1 represents a leaving group.
- This production method is a method for producing compound (Ia) which is an active ingredient of the medicament of the present invention by cyclization reaction between compound (1) and compound (2).
- the leaving group for L 1 include chloro, bromo, methoxy, and methylsulfanyl.
- Reactions include ethers such as tetrahydrofuran (THF), 1,4-dioxane, diglyme, alcohols such as methanol, ethanol, propanol, butanol, N, N-dimethylformamide (DMF), N-methylpyrrolidin-2-one ( NMP), aprotic polar solvents such as dimethylimidazolidinone, dimethylacetamide (DMA), dimethylsulfoxide (DMSO), aromatic hydrocarbons such as benzene, toluene, xylene, dichloromethane, chloroform, 1,2-dichloroethane, etc.
- the reaction can be carried out in a solvent such as halogenated hydrocarbons at room temperature or under heating conditions.
- organic acids such as acetic acid and p-toluenesulfonic acid, acids such as sulfuric acid and hydrochloric acid, or organic bases such as triethylamine, N, N-diisopropylethylamine, sodium bicarbonate, potassium carbonate, etc. It may be advantageous to carry out the reaction in the presence of an inorganic base. Depending on the compound, it may be advantageous to carry out the reaction in the presence of a phase transfer catalyst such as tetra-n-butylammonium iodide.
- a phase transfer catalyst such as tetra-n-butylammonium iodide.
- This production method is a method in which compound (3) and compound (4) are reacted to obtain compound (Ia) which is an active ingredient of the medicament of the present invention.
- the compound (3) and the compound (4) are used in an equal amount or an excess of one of them, in an alcohol, aromatic hydrocarbons such as benzene, toluene, xylene, acetic acid, etc., in a solvent inert to the reaction, Alternatively, the reaction can be performed without solvent, at room temperature or under heating, preferably under heating.
- an acid such as an organic acid such as acetic acid, p-toluenesulfonic acid, trifluoroacetic acid, or a mineral acid such as sulfuric acid or hydrochloric acid. It may also be advantageous to perform the reaction using microwaves.
- This production method is a method in which compound (5) is O-arylated to obtain compound (Ia-1) which is an active ingredient of the medicament of the present invention.
- the leaving group for L 2 include halogens such as fluoro, chloro, and bromo.
- the compound (5) and the compound (6) are used in an equal amount or in an excess amount, and in the presence of a base, an aprotic polar solvent such as DMF or DMSO, an ether or the like is an inert solvent for the reaction. In the middle, cooling can be carried out under reflux.
- the base include sodium hydride, potassium hydride, butyl lithium, potassium carbonate and the like.
- This production method is a method for producing compound (Ia), which is an active ingredient of the medicament of the present invention, by cyclization reaction between compound (7) and compound (8).
- the cyclization reaction can be carried out in the same manner as in the first production method.
- compound (9) is cyclized to obtain compound (Ia) which is an active ingredient of the medicament of the present invention.
- the cyclization reaction can be performed in a solvent such as ethers, aromatic hydrocarbons, and halogenated hydrocarbons at room temperature or under heating conditions.
- a solvent such as ethers, aromatic hydrocarbons, and halogenated hydrocarbons at room temperature or under heating conditions.
- some compounds represented by the formula (Ia) are known alkylation, acylation, substitution reaction, oxidation from the compound (Ia) which is the active ingredient of the medicament of the present invention obtained as described above. Further, it can also be produced by arbitrarily combining processes that can be usually employed by those skilled in the art, such as reduction, hydrolysis and the like.
- the raw materials used for the production of the compound (Ia) which is an active ingredient of the medicament of the present invention are, for example, the following methods, the methods described in the production examples described later, known methods or methods obvious to those skilled in the art, It can be manufactured by applying the modified method.
- L 3 represents a leaving group.
- Compound (3) can be produced by cyclizing compound (11) obtained by amidation reaction between compound (1) and compound (10).
- examples of the leaving group for L 3 include chloro, bromo, and hydroxy.
- the amidation reaction can be carried out at room temperature or under heating conditions using an equivalent amount of Compound (1) and Compound (10) or an excess of one in a solvent such as halogenated hydrocarbons or aprotic polar solvent.
- the reaction in the presence of an organic base such as triethylamine, N, N-diisopropylethylamine or pyridine, or an inorganic base such as potassium carbonate or sodium carbonate may be advantageous for the smooth progress of the reaction. is there.
- the cyclization reaction is prepared by adjusting compound (11) from phosphorus oxychloride, trifluoromethanesulfonic anhydride, triphenylphosphine and carbon tetrabromide in a solvent such as an aprotic polar solvent such as halogenated hydrocarbons. It can be performed by reacting with a dehydrating agent such as a reagent. Depending on the compound, the reaction in the presence of an organic base such as triethylamine, N, N-diisopropylethylamine or pyridine, or an inorganic base such as potassium carbonate or sodium carbonate may be advantageous for the smooth progress of the reaction. is there.
- R means lower alkyl
- L 4 means a leaving group.
- Compound (3) can also be produced by cyclization of compound (1) and compound (13).
- examples of the leaving group for L 4 include chloro and bromo. The reaction can be carried out in the same manner as in the first production method.
- Compound (9) can be produced by an amidation reaction of compound (14) and compound (15).
- the amidation reaction can be performed under the same conditions as the amidation in the first step of raw material synthesis 1.
- the compounds of formula (Ia) are isolated and purified as free compounds, their salts, hydrates, solvates or crystalline polymorphic substances.
- the salt of the compound of formula (Ia) can also be produced by subjecting it to a conventional salt formation reaction. Isolation and purification are performed by applying ordinary chemical operations such as extraction, fractional crystallization, and various fractional chromatography.
- Various isomers can be produced by selecting an appropriate raw material compound, or can be separated by utilizing a difference in physicochemical properties between isomers.
- optical isomers can be obtained by general optical resolution of racemates (for example, fractional crystallization leading to diastereomeric salts with optically active bases or acids, chromatography using chiral columns, etc.). Further, it can also be produced from a suitable optically active raw material compound.
- the pharmaceutical composition for treating pain according to the present invention containing one or more compounds of the formula (Ia) as an active ingredient is an excipient usually used in the art, that is, a pharmaceutical preparation. It can be prepared by a commonly used method using a form, a pharmaceutical carrier and the like. Administration is orally by tablets, pills, capsules, granules, powders, solutions, etc., or injections such as intra-articular, intravenous, intramuscular, suppositories, eye drops, ophthalmic ointments, transdermal solutions, Any form of parenteral administration such as an ointment, a transdermal patch, a transmucosal liquid, a transmucosal patch, and an inhalant may be used.
- a solid composition for oral administration tablets, powders, granules and the like are used.
- one or more active ingredients are mixed with at least one inert excipient.
- the composition may contain an inert additive such as a lubricant, a disintegrant, a stabilizer and a solubilizing agent according to a conventional method. If necessary, tablets or pills may be coated with a sugar coating or a film of a gastric or enteric substance.
- Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or elixirs and the like, and commonly used inert diluents such as purified water. Or it contains ethanol.
- the liquid composition may contain solubilizers, wetting agents, auxiliaries such as suspending agents, sweeteners, flavors, fragrances and preservatives in addition to the inert diluent.
- the injection for parenteral administration contains a sterile aqueous or non-aqueous solution, suspension or emulsion.
- aqueous solvent include distilled water for injection or physiological saline.
- Non-aqueous solvents include alcohols such as ethanol.
- Such compositions may further contain isotonic agents, preservatives, wetting agents, emulsifiers, dispersants, stabilizers, or solubilizing agents. These are sterilized by, for example, filtration through a bacteria-retaining filter, blending with a bactericide or irradiation. These can also be used by producing a sterile solid composition and dissolving or suspending it in sterile water or a sterile solvent for injection before use.
- External preparations include ointments, plasters, creams, jellies, poultices, sprays, lotions, eye drops, eye ointments and the like.
- ointment bases commonly used ointment bases, lotion bases, aqueous or non-aqueous solutions, suspensions, emulsions, and the like.
- a transmucosal agent such as an inhalant or a nasal agent is used in a solid, liquid, or semi-solid state, and can be produced according to a conventionally known method.
- known excipients, and further pH adjusters, preservatives, surfactants, lubricants, stabilizers, thickeners and the like may be appropriately added.
- an appropriate device for inhalation or insufflation can be used.
- a known device such as a metered dose inhalation device or a nebulizer
- the compound is administered alone or as a powder in a formulated mixture or as a solution or suspension in combination with a pharmaceutically acceptable carrier. be able to.
- the dry powder inhaler or the like may be for single or multiple administration, and a dry powder or a powder-containing capsule can be used. Alternatively, it may be in the form of a pressurized aerosol spray using a suitable propellant, for example, a suitable gas such as chlorofluoroalkane or carbon dioxide.
- a suitable propellant for example, a suitable gas such as chlorofluoroalkane or carbon dioxide.
- the appropriate daily dose is about 0.001 to 100 mg / kg, preferably 0.1 to 30 mg / kg, more preferably 0.1 to 10 mg / kg per body weight. Or in 2 to 4 divided doses.
- the appropriate daily dose is about 0.0001 to 10 mg / kg per body weight, and is administered once to several times a day.
- a transmucosal agent about 0.001 to 100 mg / kg per body weight is administered once to several times a day. The dose is appropriately determined according to individual cases in consideration of symptoms, age, sex, and the like.
- the pain therapeutic agent containing the compound of formula (Ia) or a pharmaceutically acceptable salt thereof as an active ingredient can be used in combination with other pain therapeutic agents.
- the combination may be administered simultaneously, separately separately, or at desired time intervals.
- the simultaneous administration preparation may be a combination drug or may be separately formulated.
- Example 1 Rat 11 ⁇ -HSD1 Inhibitory Activity Measurement Test The procedure for measuring 11 ⁇ -HSD1 inhibitory activity is as follows. The enzyme reaction and measurement were performed using a 384 well plate. The enzyme was prepared according to Journal of Biological Chemistry, 2001, 276, p21343-21350. Reactions consisted of 5 mM phosphate buffer (pH 6.6), 200 nM cortisone, 40 ⁇ M reduced nicotinamide adenine dinucleotide phosphate (NADPH) and rat recombinant 11 ⁇ -HSD1 in various concentrations. The compound was added and then incubated for 1 hour at room temperature (10 ⁇ L / well).
- NADPH nicotinamide adenine dinucleotide phosphate
- test compound was dissolved in dimethyl sulfoxide (DMSO) to prepare a DMSO concentration of 1% in the reaction solution.
- DMSO dimethyl sulfoxide
- the enzyme inhibitory activity was measured by detecting cortisol using a time-resolved fluorescence (HTRF) method.
- HTRF time-resolved fluorescence
- Fluorescence intensity was measured using a meter (trade name: ARVO HTS 1420, PerkinElmer / Wallac), and the fluorescence intensity ratio of two wavelengths (665 nm / 620 nm) Enzyme inhibition activity was calculated. The measurement results were calculated by averaging the values of 3 wells under the same conditions. The ratio when DMSO was added instead of the test compound was 0%, the ratio when 11 ⁇ -HSD1 was not added was 100%, and the concentration at which the test compound was inhibited by 50% was calculated as the IC 50 of the compound inhibitory activity.
- the IC 50 values of typical compounds relating to the active ingredients of the medicament of the present invention are shown in Table 1 below. Cpd indicates the compound number (the same applies hereinafter).
- Example 2 Spinal nerve ligation model test The test was performed according to Pain, 1992, Vol. 50, p355-363. Under pentobarbital anesthesia, the lumbar skin and muscles of rats (SD, male, 5-6 weeks old) were incised, and the lumbar L6 transverse process was removed to expose the lumbar nerve. The wound was sutured after ligating the L5 and L6 spinal nerves with silk thread. Treatment was given on the left side. In the case of sham surgery, the wound was sutured without performing nerve ligation. The drug efficacy was evaluated by von Frey hair test 7-20 days after surgery. The avoidance response threshold was calculated according to Journal of Neuroscience Methods, 1994, 53, p55-63.
- Example 3 Fibromyalgia model test by repeated administration of reserpine The test was performed according to Pain, 2009, 146, p26-33. Rats (SD, male, 7 weeks old) were used. Muscle tenderness threshold measurement was performed according to the method of Schafers et al. (Pain, 2003, 104, p579-588). A pressure stimulus gradually increasing up to 250 g was applied to the gastrocnemius of the rat right hind paw. The magnitude of the minimum pressure stimulation in which the rat showed an avoidance response from the pressure stimulation of the right hind paw was measured as the muscle tenderness threshold (g). Measurement was performed three times at each time point, and the average was taken as the measurement value.
- Solvent (0.5% acetic acid aqueous solution) or reserpine 1 mg / kg was subcutaneously administered to the dorsal skin once a day for 3 days. All administration volumes of solvent or reserpine were 1 mL per kg of animal body weight. Six days after the start of administration of the solvent or reserpine, the muscle tenderness threshold value of each rat was measured, and the groups were divided so that the difference in the average value of the threshold values of each group became small. The medicinal effect was evaluated the next day. The test substance was suspended in a 0.5% methylcellulose solution, and the muscle tenderness threshold was measured 30, 60, and 120 minutes after oral administration. Healthy rats were not subjected to drug administration and were only subjected to muscle tenderness threshold measurement.
- the measurement of the drug effect was performed by an experimenter who did not know the content of the drug treatment on the animal. Evaluation of the test substance was carried out when the muscle tenderness threshold of healthy rats at any time point at 30, 60, and 120 minutes after administration was 100%, and the muscle tenderness threshold of reserpine-treated rats administered the solvent was 0%. The maximum improvement rate of the substance administration group was obtained. Table 3 shows the improvement rates of typical compounds related to the active ingredients of the medicament of the present invention.
- the compound represented by the formula (Ia) was effective in various pain models. Therefore, it is clear that the compound represented by the formula (Ia) which is an active ingredient of the medicament of the present invention can be used for the treatment of pain (particularly neuropathic pain, fibromyalgia etc.).
- Compounds 1 to 15 described in Tables 4 to 6 below are all known products and can be produced as follows.
- Compounds 1 to 15 are all compounds described as Example compounds in International Publication WO2010 / 001946 Pamphlet, and can be produced by the method described in the publication.
- Compound 2 is described as Example 65 of the publication.
- the 11 ⁇ -HSD1 inhibitor particularly the compound of formula (Ia), which is an active ingredient of the medicament of the present invention, is useful for the treatment of pain (particularly neuropathic pain, fibromyalgia).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
特許文献1では、下記一般式(A)で示されるトリアゾール化合物が、11β-HSD1阻害作用を有し、糖尿病、高血糖、インスリン抵抗性、肥満、高脂血症、高血圧、骨粗鬆症、緑内障、認知症、統合失調症、うつ等の疾患の治療に有用であることが記載されている。しかしながら、疼痛の治療に対する有用性についての記載はない。
すなわち、本発明は、
(1)式(I-a)で示される化合物又はその製薬学的に許容される塩を有効成分として含有する疼痛治療剤
A環:それぞれ置換されていてもよいアリール、ヘテロ環基、又は、シクロアルキル。
R1a:それぞれ置換されていてもよいアリール若しくはヘテロ環基、又は、低級アルキレン-シクロアルキル。
R2a:低級アルキル。
R3a:-H又は低級アルキル。
或いは、R2a及びR3aが一体となって、C2-6アルキレン。
R4:低級アルキル、ハロゲノ低級アルキル、低級アルキレン-O-低級アルキル、シクロアルキル、低級アルキレン-S-低級アルキル、低級アルキレン-S(O)-低級アルキル、低級アルキレン-S(O)2-低級アルキル、又は、低級アルキレン-シクロアルキル。(以下同様。)]
(2)疼痛が神経障害性疼痛である、(1)記載の疼痛治療剤。
(3)疼痛が線維筋痛症である、(1)記載の疼痛治療剤。
に関する。
即ち、本発明は、
(4)疼痛治療薬の製造のための、式(I-a)で示される化合物またはその製薬学的に許容される塩の使用。
(5)疼痛治療のための、式(I-a)で示される化合物またはその製薬学的に許容される塩の使用。
(6)疼痛治療のための、式(I-a)で示される化合物またはその製薬学的に許容される塩。
(7)式(I-a)で示される化合物またはその製薬学的に許容される塩の治療有効量を患者に投与することを含む、疼痛治療方法。
にも関する。
(8)11β-HSD1阻害剤を有効成分として含有する線維筋痛症治療剤
にも関する。
「低級アルキル」として好ましくは直鎖又は分枝状の、炭素数が1から6(以後、C1-6と略す)のアルキル、具体的には、メチル、エチル、n-プロピル、イソプロピル、n-ブチル、イソブチル、sec-ブチル、tert-ブチル、n-ペンチル、n-ヘキシル基等である。より好ましくはC1-4アルキルであり、特に好ましくは、メチル、エチル、n-プロピル、イソプロピルである。
「ハロゲノ低級アルキル」とは、1個以上のハロゲンで置換された、低級アルキルである。好ましくは1~7個のハロゲンで置換された低級アルキルであり、より好ましくは、1~5個のハロゲンで置換された低級アルキルであり、さらにより好ましくは、フルオロメチル、ジフルオロメチル、トリフルオロメチルである。
「ハロゲノ低級アルキレン」とは、1個以上のハロゲンで置換された、低級アルキレンである。好ましくは1~7個のハロゲンで置換された低級アルキレンであり、より好ましくは、フルオロメチレン、ジフルオロメチレン、トリフルオロメチルメチレン、ビストリフルオロメチルメチレンである。
G1群:ハロゲン、シアノ、低級アルキル、ハロゲノ低級アルキル、低級アルキレン-OR0、低級アルキレン-N(R0)2、低級アルキレン-N(R0)C(O)R0、低級アルキレン-N(R0)S(O)2-低級アルキル、-OR0、-O-ハロゲノ低級アルキル、-O-シクロアルキル、-O-アリール、-O-へテロ環基、-C(O)R0、-CO2R0、-C(O)NH2、-C(O)N(R0)-(-OR0又は-CO2R0で置換されていてもよい低級アルキル)、-C(O)N(R0)-低級アルキレン-OR0、-C(O)N(R0)-低級アルキレン-N(R0)2、-C(O)N(R0)-低級アルキレン-S-低級アルキル、-C(O)N(R0)-低級アルキレン-S(O)-低級アルキル、-C(O)N(R0)-低級アルキレン-S(O)2-低級アルキル、-C(O)N(R0)-低級アルキレン-C(O)N(R0)2、-C(O)N(R0)-低級アルキレン-C(O)N(R0)-シクロアルキル、-C(O)N(R0)-低級アルキレン-ヘテロ環基、-C(O)N(R0)-シクロアルキル、-C(O)N(R0)-へテロ環基、-C(O)N(R0)N(R0)2、-C(O)N(R0)N(R0)C(O)R0、-C(O)N(R0)S(O)2-低級アルキル、-C(O)-へテロ環基、-C(=NOR0)-N(R0)2、-S-低級アルキル、-S(O)-低級アルキル、-S(O)2-低級アルキル、オキソ、及び、ヘテロ環基。
ただし、G1群におけるアリール及びヘテロ環基は下記G2群より選択される基で置換されていてもよい。
G2群:ハロゲン、シアノ、低級アルキル、ハロゲノ低級アルキル、-OR0、-O-ハロゲノ低級アルキル、-CO2R0、-C(O)N(R0)2、-C(O)N(R0)S(O)2-低級アルキル、-C(O)N(R0)S(O)2N(R0)2、シクロアルキル、及び、ヘテロ環基。
G3群:ハロゲン、シアノ、低級アルキル、ハロゲノ低級アルキル、低級アルキレン-OR0、ハロゲノ低級アルキレン-OR0、低級アルキレン-N(R0)2、低級アルキレン-アリール、-OR0、-O-ハロゲノ低級アルキル、-O-低級アルキレン-OR0、-O-低級アルキレン-N(R0)2、-O-低級アルキレン-CO2R0、-O-低級アルキレン-C(O)N(R0)2、-O-低級アルキレン-アリール、-O-アリール、-C(O)R0、-CO2R0、-CON(R0)2、-CON(R0)-低級アルキレン-OR0、-N(R0)2、-N(R0)C(O)R0、-S-低級アルキル、-S(O)-低級アルキル、-S(O)2-低級アルキル、-S(O)2-アリール、オキソ、シクロアルキル、アリール、及び、ヘテロ環基。
ただし、G3群におけるアリール、及び、ヘテロ環基は、ハロゲン、低級アルキル、ハロゲノ低級アルキル、-OR0、-O-ハロゲノ低級アルキル、-CO2R0又は-CON(R0)2で置換されていてもよい。
「疼痛」として、好ましくは、神経障害性疼痛である。また、別の態様として好ましくは、線維筋痛症である。
(1)式(I-b)で示される化合物。
R1b:置換されていてもよいアリール。
R2b:低級アルキル。
R3b:低級アルキル。
R4b:低級アルキル又はシクロアルキル。
Ab環:それぞれ置換されていてもよいアリール又はヘテロアリール。
以下同様。]
(2)式(I-c)で示される化合物。
R1c:ハロゲンで置換されたフェニル。
R4c:メチル、エチル、イソプロピル又はシクロプロピル。
Ac環:ハロゲン又は-C(O)NH2で置換されたフェニル。]
(3)Ac環が、4位が-C(O)NH2で置換され、さらにハロゲンで置換されていてもよいフェニルである、(2)記載の化合物。
(4)Ac環が、ハロゲンで置換されたフェニルである、(2)記載の化合物。
(5)3-(2-ブロモ-4-フルオロフェニル)-4-メチル-5-[1-メチル-1-(2,4,6-トリフルオロフェノキシ)エチル]-4H-1,2,4-トリアゾール、
3-(2-クロロ-4-フルオロフェニル)-4-メチル-5-[1-メチル-1-(2,4,6-トリフルオロフェノキシ)エチル]-4H-1,2,4-トリアゾール、
3-(2-クロロフェニル)-4-メチル-5-[1-メチル-1-(2,4,6-トリフルオロフェノキシ)エチル]-4H-1,2,4-トリアゾール、
3-[1-(4-クロロ-2,6-ジフルオロフェノキシ)-1-メチルエチル]-5-(2-クロロフェニル)-4-メチル-4H-1,2,4-トリアゾール、
3-[1-(4-クロロ-2,6-ジフルオロフェノキシ)-1-メチルエチル]-5-(2-クロロ-4-フルオロフェニル)-4-メチル-4H-1,2,4-トリアゾール、
3-(2-フルオロフェニル)-4-メチル-5-[1-メチル-1-(2,4,6-トリフルオロフェノキシ)エチル]-4H-1,2,4-トリアゾール、
4-メチル-3-[1-メチル-1-(2,4,6-トリフルオロフェノキシ)エチル]-5-[3-(トリフルオロメチル)-1H-ピラゾール-4-イル]-4H-1,2,4-トリアゾール、
4-{5-[1-(4-クロロ-2,6-ジフルオロフェノキシ)-1-メチルエチル]-4-エチル-4H-1,2,4-トリアゾール-3-イル}ベンズアミド、
4-{4-イソプロピル-5-[1-メチル-1-(2,4,6-トリフルオロフェノキシ)エチル]-4H-1,2,4-トリアゾール-3-イル}ベンズアミド、
4-{5-[1-(4-クロロ-2,6-ジフルオロフェノキシ)-1-メチルエチル]-4-メチル-4H-1,2,4-トリアゾール-3-イル}-3-フルオロベンズアミド、
4-{4-シクロプロピル-5-[1-(2,4-ジフルオロフェノキシ)-1-メチルエチル]-4H-1,2,4-トリアゾール-3-イル}-3-フルオロベンズアミド、
3-フルオロ-4-{4-メチル-5-[1-メチル-1-(2,4,6-トリフルオロフェノキシ)エチル]-4H-1,2,4-トリアゾール-3-イル}ベンズアミド、
4-{5-[1-(4-クロロ-2,6-ジフルオロフェノキシ)-1-メチルエチル]-4-イソプロピル-4H-1,2,4-トリアゾール-3-イル}ベンズアミド、
3-クロロ-4-{4-シクロプロピル-5-[1-メチル-1-(2,4,6-トリフルオロフェノキシ)エチル]-4H-1,2,4-トリアゾール-3-イル}ベンズアミド、及び、
3-フルオロ-4-{4-イソプロピル-5-[1-メチル-1-(2,4,6-トリフルオロフェノキシ)エチル]-4H-1,2,4-トリアゾール-3-イル}ベンズアミド
からなる群より選択される化合物。
(a)R1aとして、好ましくは、置換されていてもよいアリールであり、より好ましくは、置換されていてもよいフェニルであり、さらにより好ましくは、ハロゲンで置換されたフェニルであり、さらにより好ましくは、2位及び4位がハロゲンで置換されたフェニル、または、2位、4位及び6位がハロゲンで置換されたフェニルである。
(b)R2aとして、好ましくは、低級アルキルであり、より好ましくは、メチルである。
(c)R3aとして、好ましくは、低級アルキルであり、より好ましくは、メチルである。
(d)R4として、好ましくは、低級アルキル又はシクロアルキルであり、より好ましくは、メチル、エチル、イソプロピル、又は、シクロプロピルである。
(e)A環として、好ましくは、それぞれ置換されていてもよいアリール又はヘテロアリールであり、より好ましくは、置換されていてもよいアリールであり、さらに好ましくは、置換されていてもよいフェニルであり、さらにより好ましくは、ハロゲン又は-C(O)NH2で置換されたフェニルであり、よりさらに好ましくはハロゲンで置換されたフェニルであり、特に好ましくは、2位がハロゲンで置換されたフェニル、又は、2位及び4位がハロゲンで置換されたフェニルである。別の態様として好ましくは、-C(O)NH2で置換され、さらにハロゲンで置換されていてもよいフェニルであり、より好ましくは、4位が-C(O)NH2で置換され、さらにハロゲンで置換されていてもよいフェニルである。また、別の態様として好ましくは、ハロゲン、ハロゲノ低級アルキル及び-C(O)NH2から選択される基でそれぞれ置換されたフェニル又はピロールである。
(f)上記(a)~(e)に記載の基の二以上の組み合わせである化合物。
また、本発明医薬の有効成分である式(I-a)の化合物には、不斉炭素原子や軸不斉を有する場合があり、これに基づく光学異性体が存在しうる。本発明医薬の有効成分には、光学異性体の分離されたもの、あるいはそれらの混合物も包含する。
本発明医薬の有効成分である式(I-a)の化合物及びその塩は、その基本構造あるいは置換基の種類に基づく特徴を利用し、種々の公知の合成法を適用して製造することができる。その際、官能基の種類によっては、当該官能基を原料から中間体へ至る段階で適当な保護基(容易に当該官能基に転化可能な基)に置き換えておくことが製造技術上効果的な場合がある。このような保護基としては、例えば、ウッツ(P. G. M. Wuts)及びグリーン(T. W. Greene)著、「Greene's Protective Groups in Organic Synthesis(第4版、2006年)」に記載の保護基等を挙げることができ、これらの反応条件に応じて適宜選択して用いればよい。このような方法では、当該保護基を導入して反応を行なったあと、必要に応じて保護基を除去することにより、所望の化合物を得ることができる。
また、式(I-a)の化合物のプロドラッグは、上記保護基と同様、原料から中間体へ至る段階で特定の基を導入、あるいは得られた式(I-a)の化合物を用いてさらに反応を行なうことで製造できる。反応は通常のエステル化、アミド化、脱水等、当業者に公知の方法を適用することにより行うことができる。
以下、式(I-a)の化合物の代表的な製造法を説明する。各製法は、当該説明に付した参考文献を参照して行うこともできる。なお、本発明の製造法は以下に示した例には限定されない。
本製法は、化合物(1)と化合物(2)との環化反応により、本発明医薬の有効成分である化合物(I-a)を製造する方法である。ここで、L1の脱離基としては、例えば、クロロ、ブロモ、メトキシ、メチルスルファニル等が挙げられる。反応はテトラヒドロフラン(THF)、1,4-ジオキサン、ダイグライム等のエーテル類、メタノール、エタノール、プロパノール、ブタノール等のアルコール類、N,N-ジメチルホルムアミド(DMF)、N-メチルピロリジン-2-オン(NMP)、ジメチルイミダゾリジノン、ジメチルアセトアミド(DMA)、ジメチルスルホキシド(DMSO)等の非プロトン性極性溶媒、ベンゼン、トルエン、キシレン等の芳香族炭化水素類、ジクロロメタン、クロロホルム、1,2-ジクロロエタン等のハロゲン化炭化水素類等の溶媒中、室温下または加熱条件下に行うことが出来る。化合物によっては、酢酸、p-トルエンスルホン酸等の有機酸、硫酸、塩酸等の鉱酸等の酸存在下、もしくはトリエチルアミン、N,N-ジイソプロピルエチルアミンなどの有機塩基、炭酸水素ナトリウム、炭酸カリウムなどの無機塩基存在下、反応を行うことが有利な場合がある。化合物によっては、テトラ-n-ブチルアンモニウムヨージド等の相間移動触媒存在下反応を行うことが有利な場合がある。
反応は、化合物(3)と化合物(4)とを等量若しくは一方を過剰量用い、アルコール類、ベンゼン、トルエン、キシレン等の芳香族炭化水素類、酢酸等、反応に不活性な溶媒中、又は無溶媒下、室温下乃至加熱下、好ましくは加熱下で行うことができる。化合物によっては酢酸、p-トルエンスルホン酸、トリフルオロ酢酸等の有機酸、硫酸、塩酸等の鉱酸等の酸存在下反応を行うことが有利な場合がある。また、マイクロ波を用いて反応を行うことが有利な場合がある。
本製法は、化合物(5)をO-アリール化して、本発明医薬の有効成分である化合物(I-a-1)を得る方法である。ここで、L2の脱離基としては、例えば、フルオロ、クロロ、ブロモ等のハロゲンが挙げられる。
アリール化反応は、化合物(5)と化合物(6)とを等量若しくは一方を過剰量用い、塩基存在下、DMF、DMSOなどの非プロトン性極性溶媒、エーテル類等、反応に不活性な溶媒中、冷却化から加熱還流下行うことができる。塩基としては、水素化ナトリウム、水素化カリウム、ブチルリチウム、炭酸カリウム等が挙げられる。
環化反応は、エーテル類、芳香族炭化水素類、ハロゲン化炭化水素類等の溶媒中、室温下または加熱条件下に行うことが出来る。化合物によっては、酢酸、p-トルエンスルホン酸等の有機酸、硫酸、塩酸等の鉱酸等の酸存在下反応を行うことが、反応の進行に有利な場合がある。
化合物(3)は、化合物(1)と化合物(10)とのアミド化反応により得られた化合物(11)を環化させることにより製造することができる。ここで、L3の脱離基としては、例えば、クロロ、ブロモ、ヒドロキシ等が挙げられる。
アミド化反応はハロゲン化炭化水素類、非プロトン性極性溶媒等の溶媒中、化合物(1)と化合物(10)を等量又は一方を過剰量用い室温下乃至加熱条件下で行うことが出来る。化合物によっては、トリエチルアミン、N,N-ジイソプロピルエチルアミン若しくはピリジン等の有機塩基、又は炭酸カリウム若しくは炭酸ナトリウム等の無機塩基の存在下に反応させるのが、反応を円滑に進行させる上で有利な場合がある。
L3の脱離基がヒドロキシの場合、1-(3-ジメチルアミノプロピル)-3-エチルカルボジイミド(WSC)、ジシクロヘキシルカルボジイミド(DCC)、1,1’-カルボニルジイミダゾール(CDI)、O-(ベンゾトリアゾール-1-イル)-N,N,N',N'-テトラメチルウロニウムヘキサフルオロホスファート(HBTU)等の縮合剤の存在下、反応を行うことが好ましい。また、さらに添加剤(例えば1-ヒドロキシベンゾトリアゾール(HOBt)、1-ヒドロキシ-7-アザベンゾトリアゾール(HOAt)等)を用いることが好ましい場合がある。
環化反応は、ハロゲン化炭化水素類などの非プロトン性極性溶媒等の溶媒中、化合物(11)をオキシ塩化リン、トリフルオロメタンスルホン酸無水物、トリフェニルホスフィンと四臭化炭素より調整される試薬などの脱水剤と反応させることにより行うことが出来る。化合物によっては、トリエチルアミン、N,N-ジイソプロピルエチルアミン若しくはピリジン等の有機塩基、又は炭酸カリウム若しくは炭酸ナトリウム等の無機塩基の存在下に反応させるのが、反応を円滑に進行させる上で有利な場合がある。
また、化合物(3)は、化合物(1)と化合物(13)との環化によっても製造することができる。ここで、L4の脱離基としては、例えば、クロロ、ブロモ等が挙げられる。
反応は、第一製法と同様にして行なうことができる。
単離、精製は、抽出、分別結晶化、各種分画クロマトグラフィー等、通常の化学操作を適用して行なわれる。
各種の異性体は、適当な原料化合物を選択することにより製造でき、あるいは異性体間の物理化学的性質の差を利用して分離することができる。例えば、光学異性体は、ラセミ体の一般的な光学分割法(例えば、光学活性な塩基又は酸とのジアステレオマー塩に導く分別結晶化や、キラルカラム等を用いたクロマトグラフィー等)により得られ、また、適当な光学活性な原料化合物から製造することもできる。
投与は錠剤、丸剤、カプセル剤、顆粒剤、散剤、液剤等による経口投与、又は、関節内、静脈内、筋肉内等の注射剤、坐剤、点眼剤、眼軟膏、経皮用液剤、軟膏剤、経皮用貼付剤、経粘膜液剤、経粘膜貼付剤、吸入剤等による非経口投与のいずれの形態であってもよい。
経口投与のための液体組成物は、薬剤的に許容される乳濁剤、溶液剤、懸濁剤、シロップ剤又はエリキシル剤等を含み、一般的に用いられる不活性な希釈剤、例えば精製水又はエタノールを含む。当該液体組成物は不活性な希釈剤以外に可溶化剤、湿潤剤、懸濁剤のような補助剤、甘味剤、風味剤、芳香剤、防腐剤を含有していてもよい。
11β-HSD1阻害活性測定の手順は、以下の通りである。なお酵素反応および測定は384ウェルプレートを用いて行った。酵素は、Journal of Biological Chemistry, 2001年, 276巻, p21343-21350 に従って調製した。反応は5 mM リン酸緩衝液(pH6.6)、200 nM コルチゾン、40 μM 還元型ニコチンアミドアデニンジヌクレオチドリン酸(NADPH)、ラット組換え体11β-HSD1からなる反応液に種々の濃度の被験化合物を加えた後、室温で1時間インキュベーションすることで行った(10 μL/ウェル)。被験化合物はジメチルスルホキシド(DMSO)に溶解し、反応液中DMSO濃度が1%になるよう調製した。酵素反応後、コルチゾルを時間分解蛍光測定法(Homogeneous time-resolved fluorescence(HTRF))を用いて検出することで酵素阻害活性を測定した。400 μM カルベノキソロンを含むd2標識コルチゾルおよびクリプテート(Cryptate)標識コルチゾル抗体(シー・アイ・エス・バイオ・インターナショナル(CIS bio international)社)をそれぞれ5 μL/ウェル加え、室温で2時間インキュベーション後、蛍光光度計(商品名:アルボ エイチティーエス 1420 (ARVO HTS 1420)、パーキンエルマー(PerkinElmer)/ワラック(Wallac)社)を用いて蛍光強度を測定し、2波長の蛍光強度比(665 nm/620 nm)から酵素阻害活性を算出した。
測定結果は、同一条件である3ウェルの値を平均して算出した。被験化合物の代わりにDMSOを添加した時の比を0%とし、11β-HSD1を添加しない場合の比を100%とし、被験化合物が50%抑制する濃度を化合物阻害活性のIC50として算出した。
本発明医薬の有効成分に係る代表的化合物のIC50値を下記表1に示す。尚、Cpdは化合物番号を示す(以下同様)。
Pain, 1992年, 50巻, p355-363 に従い実施した。ペントバルビタール麻酔下にラット(SD、雄性、5-6週齡)の腰部皮膚および筋肉を切開、腰椎L6の横突起を除去して腰神経を露出させた。L5およびL6脊髄神経を絹糸で結紮した後に傷口を縫合した。処置は左側に施した。なお偽手術の場合、神経結紮は実施せずに傷口を縫合した。
薬効評価は手術7-20日後にvon Frey hair試験によって実施した。回避反応閾値は、Journal of Neuroscience Methods, 1994年, 53巻, p55-63 に従い算出した。8種類のvon Frey フィラメント(0.41-15.14 g)を用いて後肢裏を刺激し、上げ下げ法によって50%回避反応閾値を決定した。試験は2.04 gのフィラメントから開始し、肢の回避反応が認められた場合を反応ありとした。
薬効評価前日にvon Frey hair試験により閾値が低下している個体をあらかじめ選別し、各群の閾値の平均値の差が小さくなるように群分けを行った。
被験物質は0.5%メチルセルロース溶液に懸濁し、薬効評価の2時間前に経口投与した。被験物質の評価は、偽手術動物群の処置側肢の閾値を100%、溶媒を投与した手術動物群の処置側肢の閾値を0%とした際の、被験物質投与群の改善率を求めることにより行った。
本発明医薬の有効成分に係る代表的化合物の改善率を下記表2に示す。
Pain, 2009年, 146巻, p26-33 に従い実施した。ラット(SD、雄性、7週齡)を用いた。
筋圧痛閾値測定はSchafersらの方法(Pain, 2003年, 104巻, p579-588)に従って実施した。ラットの右後ろ足の腓腹筋に対して最大250 gまで徐々に増加する圧刺激を加えた。ラットが右後ろ足の圧刺激からの回避反応を示す最小の圧刺激の大きさを筋圧痛閾値(g)として測定した。各時点において測定を3回ずつ行い、その平均を測定値とした。
溶媒(0.5 %酢酸水)もしくはレセルピン1 mg/kgを1日1回、3日間、背部皮下に皮下投与した。溶媒あるいはレセルピンの投与容量は全て動物体重1 kgあたり1 mLとした。溶媒あるいはレセルピン投与開始6日後に各ラットの筋圧痛閾値を測定し、各群の閾値の平均値の差が小さくなるよう群分けを行った。
薬効評価はその翌日に実施した。被験物質は0.5%メチルセルロース溶液に懸濁し、経口投与30、60、120分後に筋圧痛閾値を測定した。健常ラットには薬物投与を行わず筋圧痛閾値測定のみ実施した。薬物効果の測定は動物への薬物処置内容を知らない実験者が行った。被験物質の評価は、投与30、60、120分後のいずれかの時点における健常ラットの筋圧痛閾値を100%、溶媒を投与したレセルピン処置ラットの筋圧痛閾値を0%とした際の、被験物質投与群の最大改善率を求めることにより行った。
本発明医薬の有効成分に係る代表的化合物の改善率を下記表3に示す。
後記表4~6に記載した化合物1~15は、いずれも公知物であり、以下のようにして製造することができる。
化合物1~15は、いずれも国際公開WO2010/001946号パンフレットに実施例化合物として記載されている化合物であり、当該公報記載の方法により製造することができる。例えば、化合物2は、当該公報の実施例65として記載されている。
Cpd:化合物番号、Structure:構造式(構造式中に、HClが記載されている場合、その化合物が塩酸塩であることを示す。)
Claims (12)
- 式(I-a)で示される化合物又はその製薬学的に許容される塩を有効成分として含有する疼痛治療剤。
A環:それぞれ置換されていてもよいアリール、ヘテロ環基、又は、シクロアルキル。
R1a:それぞれ置換されていてもよいアリール若しくはヘテロ環基、又は、低級アルキレン-シクロアルキル。
R2a:低級アルキル。
R3a:-H又は低級アルキル。
或いは、R2a及びR3aが一体となって、C2-6アルキレン。
R4:低級アルキル、ハロゲノ低級アルキル、低級アルキレン-O-低級アルキル、シクロアルキル、低級アルキレン-S-低級アルキル、低級アルキレン-S(O)-低級アルキル、低級アルキレン-S(O)2-低級アルキル、又は、低級アルキレン-シクロアルキル。]
- Ac環が、4位が-C(O)NH2で置換され、さらにハロゲンで置換されていてもよいフェニルである、請求項3記載の疼痛治療剤。
- Ac環が、ハロゲンで置換されたフェニルである、請求項3記載の疼痛治療剤。
- 請求項1の式(I-a)で示される化合物又はその製薬学的に許容される塩が、
3-(2-ブロモ-4-フルオロフェニル)-4-メチル-5-[1-メチル-1-(2,4,6-トリフルオロフェノキシ)エチル]-4H-1,2,4-トリアゾール、
3-(2-クロロ-4-フルオロフェニル)-4-メチル-5-[1-メチル-1-(2,4,6-トリフルオロフェノキシ)エチル]-4H-1,2,4-トリアゾール、
3-(2-クロロフェニル)-4-メチル-5-[1-メチル-1-(2,4,6-トリフルオロフェノキシ)エチル]-4H-1,2,4-トリアゾール、
3-[1-(4-クロロ-2,6-ジフルオロフェノキシ)-1-メチルエチル]-5-(2-クロロフェニル)-4-メチル-4H-1,2,4-トリアゾール、
3-[1-(4-クロロ-2,6-ジフルオロフェノキシ)-1-メチルエチル]-5-(2-クロロ-4-フルオロフェニル)-4-メチル-4H-1,2,4-トリアゾール、
3-(2-フルオロフェニル)-4-メチル-5-[1-メチル-1-(2,4,6-トリフルオロフェノキシ)エチル]-4H-1,2,4-トリアゾール、
4-メチル-3-[1-メチル-1-(2,4,6-トリフルオロフェノキシ)エチル]-5-[3-(トリフルオロメチル)-1H-ピラゾール-4-イル]-4H-1,2,4-トリアゾール、
4-{5-[1-(4-クロロ-2,6-ジフルオロフェノキシ)-1-メチルエチル]-4-エチル-4H-1,2,4-トリアゾール-3-イル}ベンズアミド、
4-{4-イソプロピル-5-[1-メチル-1-(2,4,6-トリフルオロフェノキシ)エチル]-4H-1,2,4-トリアゾール-3-イル}ベンズアミド、
4-{5-[1-(4-クロロ-2,6-ジフルオロフェノキシ)-1-メチルエチル]-4-メチル-4H-1,2,4-トリアゾール-3-イル}-3-フルオロベンズアミド、
4-{4-シクロプロピル-5-[1-(2,4-ジフルオロフェノキシ)-1-メチルエチル]-4H-1,2,4-トリアゾール-3-イル}-3-フルオロベンズアミド、
3-フルオロ-4-{4-メチル-5-[1-メチル-1-(2,4,6-トリフルオロフェノキシ)エチル]-4H-1,2,4-トリアゾール-3-イル}ベンズアミド、
4-{5-[1-(4-クロロ-2,6-ジフルオロフェノキシ)-1-メチルエチル]-4-イソプロピル-4H-1,2,4-トリアゾール-3-イル}ベンズアミド、
3-クロロ-4-{4-シクロプロピル-5-[1-メチル-1-(2,4,6-トリフルオロフェノキシ)エチル]-4H-1,2,4-トリアゾール-3-イル}ベンズアミド、及び、
3-フルオロ-4-{4-イソプロピル-5-[1-メチル-1-(2,4,6-トリフルオロフェノキシ)エチル]-4H-1,2,4-トリアゾール-3-イル}ベンズアミド
からなる群より選択される化合物又はその製薬学的に許容される塩である、請求項1記載の疼痛治療剤。
- 疼痛が神経障害性疼痛である、請求項1乃至6記載の疼痛治療剤。
- 疼痛が線維筋痛症である、請求項1乃至6記載の疼痛治療剤。
- 疼痛治療薬の製造のための、請求項1の式(I-a)で示される化合物またはその製薬学的に許容される塩の使用。
- 疼痛治療のための、請求項1の式(I-a)で示される化合物またはその製薬学的に許容される塩の使用。
- 疼痛治療のための、請求項1の式(I-a)で示される化合物またはその製薬学的に許容される塩。
- 請求項1の式(I-a)で示される化合物またはその製薬学的に許容される塩の治療有効量を患者に投与することを含む、疼痛治療方法。
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAA201304329A UA112418C2 (uk) | 2010-09-07 | 2011-06-09 | Терапевтичний болезаспокійливий засіб |
EP11823545.6A EP2614824B1 (en) | 2010-09-07 | 2011-09-06 | Triazole derivative for use in the treatment of neuropathic pain and fibromyalgia |
ES11823545.6T ES2533310T3 (es) | 2010-09-07 | 2011-09-06 | Derivado de triazol para uso en el tratamiento del dolor neuropático y de la fibromialgia |
KR1020137008722A KR101747486B1 (ko) | 2010-09-07 | 2011-09-06 | 동통 치료제 |
CN201180042963.2A CN103079564B (zh) | 2010-09-07 | 2011-09-06 | 疼痛治疗剂 |
AU2011299905A AU2011299905B2 (en) | 2010-09-07 | 2011-09-06 | Therapeutic agent for pain |
CA2809778A CA2809778C (en) | 2010-09-07 | 2011-09-06 | Therapeutic agent for pain |
SI201130469T SI2614824T1 (sl) | 2010-09-07 | 2011-09-06 | Triazolni derivat za uporabo pri zdravljenju nevropatske bolečine in fibromialgije |
DK11823545.6T DK2614824T3 (en) | 2010-09-07 | 2011-09-06 | TRIAZOLD DERIVATIVES TO USE IN THE TREATMENT OF NEUROPATHIC PAIN AND FIBROMYALGIA |
US13/820,873 US9765040B2 (en) | 2010-09-07 | 2011-09-06 | Therapeutic agent for pain |
BR112013005532A BR112013005532A2 (pt) | 2010-09-07 | 2011-09-06 | agente terapêutico para dor |
MX2013002649A MX2013002649A (es) | 2010-09-07 | 2011-09-06 | Agente terapeutico contra el dolor. |
EA201390345A EA022338B1 (ru) | 2010-09-07 | 2011-09-06 | Применение производных триазола для лечения боли |
PL11823545T PL2614824T3 (pl) | 2010-09-07 | 2011-09-06 | Pochodna triazolowa do stosowania w leczeniu bólu neuropatycznego i fibromialgii |
JP2012532977A JP5822079B2 (ja) | 2010-09-07 | 2011-09-06 | 疼痛治療剤 |
ZA2013/01458A ZA201301458B (en) | 2010-09-07 | 2013-02-26 | Therapeutic agent for pain |
IL224920A IL224920A (en) | 2010-09-07 | 2013-02-26 | Derivatives of 4, 2, 1 - triazole for use in pain treatment |
HRP20150544TT HRP20150544T1 (hr) | 2010-09-07 | 2015-05-21 | Derivat triazola za uporabu u lijeäśenju neuropatskih bolova i fibromialgije |
US15/664,733 US20170327474A1 (en) | 2010-09-07 | 2017-07-31 | Therapeutic agent for pain |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-200305 | 2010-09-07 | ||
JP2010200305 | 2010-09-07 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/820,873 A-371-Of-International US9765040B2 (en) | 2010-09-07 | 2011-09-06 | Therapeutic agent for pain |
US15/664,733 Division US20170327474A1 (en) | 2010-09-07 | 2017-07-31 | Therapeutic agent for pain |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012033070A1 true WO2012033070A1 (ja) | 2012-03-15 |
Family
ID=45810669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/070205 WO2012033070A1 (ja) | 2010-09-07 | 2011-09-06 | 疼痛治療剤 |
Country Status (22)
Country | Link |
---|---|
US (2) | US9765040B2 (ja) |
EP (1) | EP2614824B1 (ja) |
JP (1) | JP5822079B2 (ja) |
KR (1) | KR101747486B1 (ja) |
CN (2) | CN103079564B (ja) |
AU (1) | AU2011299905B2 (ja) |
BR (1) | BR112013005532A2 (ja) |
CA (1) | CA2809778C (ja) |
CY (1) | CY1116274T1 (ja) |
DK (1) | DK2614824T3 (ja) |
EA (1) | EA022338B1 (ja) |
ES (1) | ES2533310T3 (ja) |
HR (1) | HRP20150544T1 (ja) |
IL (1) | IL224920A (ja) |
MX (1) | MX2013002649A (ja) |
PL (1) | PL2614824T3 (ja) |
PT (1) | PT2614824E (ja) |
SI (1) | SI2614824T1 (ja) |
TW (1) | TWI486336B (ja) |
UA (1) | UA112418C2 (ja) |
WO (1) | WO2012033070A1 (ja) |
ZA (1) | ZA201301458B (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013058258A1 (ja) | 2011-10-18 | 2013-04-25 | アステラス製薬株式会社 | 二環式ヘテロ環化合物 |
US9994658B2 (en) | 2015-10-02 | 2018-06-12 | Exxonmobil Chemical Patents Inc. | Polymerization process using bis phenolate compounds supported on organoaluminum treated layered silicate supports |
WO2018117063A1 (ja) * | 2016-12-20 | 2018-06-28 | アステラス製薬株式会社 | 焦燥性興奮治療剤 |
JP2022507103A (ja) * | 2018-11-20 | 2022-01-18 | スパロー ファーマシューティカルズ,インコーポレーテッド | コルチコステロイドを投与する方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2643583C1 (ru) * | 2016-10-24 | 2018-02-02 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО УГМУ Минздрава России) | Способ лечения хронических болевых синдромов, сформировавшихся на основе посттравматического стрессового расстройства, сочетающегося с последствиями боевой черепно-мозговой травмы |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003040110A1 (en) * | 2001-11-09 | 2003-05-15 | Fujisawa Pharmaceutical Co., Ltd. | Triazole derivatives as cyclooxygenase (cox) inhibitors |
WO2003104207A2 (en) | 2002-06-10 | 2003-12-18 | Merck & Co., Inc. | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
US20040133011A1 (en) | 2002-12-20 | 2004-07-08 | Waddell Sherman T. | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
WO2005044192A2 (en) | 2003-10-28 | 2005-05-19 | Amgen Inc. | Triazole compounds and uses related thereto |
JP2005170939A (ja) * | 2003-11-20 | 2005-06-30 | Takeda Chem Ind Ltd | 糖尿病の予防・治療剤 |
WO2005060963A1 (en) | 2003-12-19 | 2005-07-07 | Pfizer Inc. | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
WO2006030805A1 (ja) | 2004-09-16 | 2006-03-23 | Astellas Pharma Inc. | トリアゾール誘導体またはその塩 |
WO2006134481A1 (en) | 2005-06-16 | 2006-12-21 | Pfizer Inc. | Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1 |
WO2006134467A1 (en) | 2005-06-16 | 2006-12-21 | Pfizer Inc. | N-(pyridin-2-yl)-sulfonamide derivatives |
WO2007040982A1 (en) * | 2005-09-29 | 2007-04-12 | Astrazeneca Ab | 5- (phenylisoxazolylethoxy) -triazol- 3 -yl substituted pyridine compounds for the treatment of neurological, psychiatric or pain disorders |
WO2007105751A1 (ja) | 2006-03-16 | 2007-09-20 | Astellas Pharma Inc. | キノロン誘導体又はその製薬学的に許容される塩 |
WO2010001946A1 (ja) | 2008-07-03 | 2010-01-07 | アステラス製薬株式会社 | トリアゾール誘導体またはその塩 |
WO2011068927A2 (en) | 2009-12-04 | 2011-06-09 | Abbott Laboratories | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1894241A (zh) | 2002-08-09 | 2007-01-10 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体-5调节剂的“1,2,4” 噁二唑 |
ATE482747T1 (de) | 2003-04-11 | 2010-10-15 | High Point Pharmaceuticals Llc | Neue amide derivate und deren pharmazeutische verwendungen |
JP2008502301A (ja) * | 2003-10-10 | 2008-01-31 | ノボ ノルディスク アクティーゼルスカブ | ペプチドの抱合 |
US7507832B2 (en) | 2003-12-22 | 2009-03-24 | Eli Lilly And Company | Triazole PPAR modulators |
EP1812407A2 (en) | 2004-11-02 | 2007-08-01 | Pfizer, Inc. | Novel compounds of substituted and unsubstituted adamantyl amides |
CN101198605A (zh) | 2005-06-16 | 2008-06-11 | 辉瑞大药厂 | N-(吡啶-2-基)-磺酰胺衍生物 |
US7853951B2 (en) * | 2005-07-25 | 2010-12-14 | Intel Corporation | Lock sequencing to reorder and grant lock requests from multiple program threads |
EP1922068A4 (en) * | 2005-08-16 | 2010-08-11 | Icagen Inc | INHIBITORS OF VOLTAGE-CONTROLLED SODIUM CHANNELS |
RU2008140940A (ru) | 2006-03-16 | 2010-04-27 | Астеллас Фарма Инк. (Jp) | Производное триазола или его соль |
FR2948211B1 (fr) * | 2009-07-17 | 2011-08-05 | Airbus Operations Sas | Methode de routage des liaisons physiques d'une plateforme avionique |
-
2011
- 2011-06-09 UA UAA201304329A patent/UA112418C2/uk unknown
- 2011-09-06 CN CN201180042963.2A patent/CN103079564B/zh not_active Expired - Fee Related
- 2011-09-06 EP EP11823545.6A patent/EP2614824B1/en active Active
- 2011-09-06 TW TW100132078A patent/TWI486336B/zh not_active IP Right Cessation
- 2011-09-06 EA EA201390345A patent/EA022338B1/ru not_active IP Right Cessation
- 2011-09-06 ES ES11823545.6T patent/ES2533310T3/es active Active
- 2011-09-06 PL PL11823545T patent/PL2614824T3/pl unknown
- 2011-09-06 US US13/820,873 patent/US9765040B2/en not_active Expired - Fee Related
- 2011-09-06 KR KR1020137008722A patent/KR101747486B1/ko active IP Right Grant
- 2011-09-06 MX MX2013002649A patent/MX2013002649A/es active IP Right Grant
- 2011-09-06 CN CN201710421919.1A patent/CN107041885A/zh active Pending
- 2011-09-06 WO PCT/JP2011/070205 patent/WO2012033070A1/ja active Application Filing
- 2011-09-06 SI SI201130469T patent/SI2614824T1/sl unknown
- 2011-09-06 AU AU2011299905A patent/AU2011299905B2/en not_active Ceased
- 2011-09-06 BR BR112013005532A patent/BR112013005532A2/pt not_active Application Discontinuation
- 2011-09-06 JP JP2012532977A patent/JP5822079B2/ja not_active Expired - Fee Related
- 2011-09-06 PT PT118235456T patent/PT2614824E/pt unknown
- 2011-09-06 CA CA2809778A patent/CA2809778C/en not_active Expired - Fee Related
- 2011-09-06 DK DK11823545.6T patent/DK2614824T3/en active
-
2013
- 2013-02-26 IL IL224920A patent/IL224920A/en not_active IP Right Cessation
- 2013-02-26 ZA ZA2013/01458A patent/ZA201301458B/en unknown
-
2015
- 2015-05-13 CY CY20151100424T patent/CY1116274T1/el unknown
- 2015-05-21 HR HRP20150544TT patent/HRP20150544T1/hr unknown
-
2017
- 2017-07-31 US US15/664,733 patent/US20170327474A1/en not_active Abandoned
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003040110A1 (en) * | 2001-11-09 | 2003-05-15 | Fujisawa Pharmaceutical Co., Ltd. | Triazole derivatives as cyclooxygenase (cox) inhibitors |
WO2003104207A2 (en) | 2002-06-10 | 2003-12-18 | Merck & Co., Inc. | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
WO2003104208A1 (en) | 2002-06-10 | 2003-12-18 | Merck & Co., Inc. | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
US20040133011A1 (en) | 2002-12-20 | 2004-07-08 | Waddell Sherman T. | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
WO2005044192A2 (en) | 2003-10-28 | 2005-05-19 | Amgen Inc. | Triazole compounds and uses related thereto |
JP2005170939A (ja) * | 2003-11-20 | 2005-06-30 | Takeda Chem Ind Ltd | 糖尿病の予防・治療剤 |
WO2005060963A1 (en) | 2003-12-19 | 2005-07-07 | Pfizer Inc. | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
WO2006030805A1 (ja) | 2004-09-16 | 2006-03-23 | Astellas Pharma Inc. | トリアゾール誘導体またはその塩 |
WO2006134481A1 (en) | 2005-06-16 | 2006-12-21 | Pfizer Inc. | Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1 |
WO2006134467A1 (en) | 2005-06-16 | 2006-12-21 | Pfizer Inc. | N-(pyridin-2-yl)-sulfonamide derivatives |
WO2007040982A1 (en) * | 2005-09-29 | 2007-04-12 | Astrazeneca Ab | 5- (phenylisoxazolylethoxy) -triazol- 3 -yl substituted pyridine compounds for the treatment of neurological, psychiatric or pain disorders |
WO2007105751A1 (ja) | 2006-03-16 | 2007-09-20 | Astellas Pharma Inc. | キノロン誘導体又はその製薬学的に許容される塩 |
WO2010001946A1 (ja) | 2008-07-03 | 2010-01-07 | アステラス製薬株式会社 | トリアゾール誘導体またはその塩 |
WO2011068927A2 (en) | 2009-12-04 | 2011-06-09 | Abbott Laboratories | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF |
Non-Patent Citations (23)
Title |
---|
"Bunshi Sekkei", vol. 7, 1990, HIROKAWA PUBLISHING COMPANY, article "lyakuhin no Kaihatsu", pages: 163 - 198 |
ARTHRITIS & RHEUMATISM, vol. 33, 1990, pages 160 - 172 |
ARTHRITIS & RHEUMATISM, vol. 52, 2005, pages 2495 - 2505 |
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol. 96, 2005, pages 399 - 409 |
CLINICAL THERAPEUTICS, vol. 25, 2003, pages 2506 - 2538 |
ENDOCRINOLOGY, vol. 127, 1990, pages 1450 - 1455 |
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, 2000, pages 34841 - 34844 |
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, 2001, pages 21343 - 21350 |
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, 2001, pages 41293 - 41300 |
JOURNAL OF NEUROSCIENCE METHODS, vol. 53, 1994, pages 55 - 63 |
JOURNAL OF RHEUMATOLOGY, vol. 35, 2008, pages 502 - 514 |
JOURNAL OF STEROID BIOCHEMISTRY & MOLECULAR BIOLOGY, vol. 119, 2010, pages 1 - 13 |
LANCET, vol. 353, 1999, pages 1959 - 1966 |
P. G. M. WUTS; T. W. GREENE: "Greene's Protective Groups in Organic Synthesis", 2006 |
PAIN, vol. 136, 2008, pages 432 - 444 |
PAIN, vol. 146, 2009, pages 26 - 33 |
PAIN, vol. 50, 1992, pages 355 - 363 |
PROCEEDING OF THE NATIONAL ACADEMY OF SCIENCE, vol. 101, 2004, pages 6734 - 6739 |
PROCEEDING OF THE NATIONAL ACADEMY OF SCIENCE, vol. 98, 2001, pages 4716 - 4721 |
PROG. MED., vol. 5, 1985, pages 2157 - 2161 |
SCHAFERS ET AL., PAIN, vol. 104, 2003, pages 579 - 588 |
See also references of EP2614824A4 * |
STAAB C.A. ET AL.: "11beta-Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation", JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 119, no. 1-2, February 2010 (2010-02-01), pages 56 - 72, XP026917402 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013058258A1 (ja) | 2011-10-18 | 2013-04-25 | アステラス製薬株式会社 | 二環式ヘテロ環化合物 |
KR20140081860A (ko) | 2011-10-18 | 2014-07-01 | 아스텔라스세이야쿠 가부시키가이샤 | 이환식 헤테로환 화합물 |
US9266840B2 (en) | 2011-10-18 | 2016-02-23 | Astellas Pharma Inc. | Bicyclic heterocyclic compound |
US9994658B2 (en) | 2015-10-02 | 2018-06-12 | Exxonmobil Chemical Patents Inc. | Polymerization process using bis phenolate compounds supported on organoaluminum treated layered silicate supports |
WO2018117063A1 (ja) * | 2016-12-20 | 2018-06-28 | アステラス製薬株式会社 | 焦燥性興奮治療剤 |
JP2022507103A (ja) * | 2018-11-20 | 2022-01-18 | スパロー ファーマシューティカルズ,インコーポレーテッド | コルチコステロイドを投与する方法 |
JP7472122B2 (ja) | 2018-11-20 | 2024-04-22 | スパロー ファーマシューティカルズ,インコーポレーテッド | コルチコステロイドを投与する方法 |
Also Published As
Publication number | Publication date |
---|---|
US20130165491A1 (en) | 2013-06-27 |
HRP20150544T1 (hr) | 2015-06-19 |
TW201302717A (zh) | 2013-01-16 |
KR20130114125A (ko) | 2013-10-16 |
ZA201301458B (en) | 2014-06-25 |
EP2614824A1 (en) | 2013-07-17 |
DK2614824T3 (en) | 2015-03-23 |
KR101747486B1 (ko) | 2017-06-14 |
JPWO2012033070A1 (ja) | 2014-01-20 |
EP2614824B1 (en) | 2015-03-11 |
EP2614824A4 (en) | 2014-02-12 |
CN107041885A (zh) | 2017-08-15 |
EA201390345A1 (ru) | 2013-07-30 |
UA112418C2 (uk) | 2016-09-12 |
PL2614824T3 (pl) | 2015-08-31 |
TWI486336B (zh) | 2015-06-01 |
AU2011299905A1 (en) | 2013-03-21 |
SI2614824T1 (sl) | 2015-05-29 |
CN103079564A (zh) | 2013-05-01 |
EA022338B1 (ru) | 2015-12-30 |
MX2013002649A (es) | 2013-04-05 |
AU2011299905B2 (en) | 2015-02-26 |
US20170327474A1 (en) | 2017-11-16 |
PT2614824E (pt) | 2015-05-28 |
IL224920A (en) | 2017-05-29 |
JP5822079B2 (ja) | 2015-11-24 |
CN103079564B (zh) | 2017-06-23 |
BR112013005532A2 (pt) | 2016-05-03 |
CA2809778C (en) | 2017-12-12 |
ES2533310T3 (es) | 2015-04-09 |
CA2809778A1 (en) | 2012-03-15 |
US9765040B2 (en) | 2017-09-19 |
CY1116274T1 (el) | 2017-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5423675B2 (ja) | アゾール化合物 | |
US20170327474A1 (en) | Therapeutic agent for pain | |
DK2298747T3 (en) | TRIAZOLD DERIVATIVES OR SALTS THEREOF | |
JP2010502618A (ja) | セロトニン5−ht2a受容体のモジュレータとしてのベンゾフラン誘導体 | |
JP6402115B2 (ja) | 神経学的疾患および状態の処置に有用なスピロ−キナゾリノン誘導体 | |
AU2012327076B2 (en) | Bicyclic heterocyclic compound | |
JP6985271B2 (ja) | アルキニルジヒドロキノリンスルホンアミド化合物 | |
CA2813063A1 (en) | Antagonist for mutated androgen receptor | |
JP4774436B2 (ja) | 5ht5aレセプターアンタゴニストとしての2−アニリノ−3,4−ジヒドロ−キナゾリンの使用 | |
JP4796622B2 (ja) | (3,4−ジヒドロ−キナゾリン−2−イル)−インダン−1−イル−アミン | |
TW201144311A (en) | Azaisoquionolinone derivatives as NK3 antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180042963.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11823545 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012532977 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12013500371 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 2809778 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13820873 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/002649 Country of ref document: MX Ref document number: 2011823545 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2011299905 Country of ref document: AU Date of ref document: 20110906 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201390345 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 20137008722 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201304329 Country of ref document: UA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013005532 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013005532 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130307 |